118 related articles for article (PubMed ID: 11504367)
21. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
Schilder RJ; Goldberg M; Millenson MM; Movsas B; Rogatko A; Rogers B; Langer CJ
Lung Cancer; 2000 Jan; 27(1):37-45. PubMed ID: 10672782
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy (CTM) for breast cancer.
Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
[TBL] [Abstract][Full Text] [Related]
23. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
[TBL] [Abstract][Full Text] [Related]
24. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Meisenberg BR; Miller WE; McMillan R
Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
[TBL] [Abstract][Full Text] [Related]
25. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Scagliotti GV; Ricardi U; Crinó L; Maranzano E; De Marinis F; Morandi MG; Meacci L; Marangolo M; Emiliani E; Rosti G; Figoli F; Bolzicco G; Masiero P; Gentile A; Tonato M
Cancer Chemother Pharmacol; 1996; 38(6):561-5. PubMed ID: 8823499
[TBL] [Abstract][Full Text] [Related]
27. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.
van der Wall E; Nooijen WJ; Baars JW; Holtkamp MJ; Schorangel JH; Richel DJ; Rutgers EJ; Slaper-Cortenbach IC; van der Schoot CE; Rodenhuis S
Br J Cancer; 1995 Apr; 71(4):857-62. PubMed ID: 7536025
[TBL] [Abstract][Full Text] [Related]
28. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract][Full Text] [Related]
29. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
[TBL] [Abstract][Full Text] [Related]
30. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
31. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
VanderWalde A; Ye W; Frankel P; Asuncion D; Leong L; Luu T; Morgan R; Twardowski P; Koczywas M; Pezner R; Paz IB; Margolin K; Wong J; Doroshow JH; Forman S; Shibata S; Somlo G
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1273-80. PubMed ID: 22306735
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer.
Schwartzberg LS; Weaver CH; Birch R; Manner C; Tauer K; Beeker T; Morgan-Ihrig C; MacAneny B; Leff R; Smith R; Hainsworth J; Greco T; Schwerkoske J; Murphy MN; Buckner CD
J Hematother; 1998 Apr; 7(2):141-50. PubMed ID: 9597571
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
[TBL] [Abstract][Full Text] [Related]
35. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
[TBL] [Abstract][Full Text] [Related]
36. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.
Ayash LJ; Elias A; Ibrahim J; Schwartz G; Wheeler C; Reich E; Lynch C; Warren D; Shapiro C; Richardson P; Hurd D; Schnipper L; Frei E; Antman K
J Clin Oncol; 1998 Mar; 16(3):1000-7. PubMed ID: 9508183
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
[TBL] [Abstract][Full Text] [Related]
38. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of high-dose chemotherapy with autologous stem cell transplantation for patients with malignant astrocytomas.
Chen B; Ahmed T; Mannancheril A; Gruber M; Benzil DL
Cancer; 2004 May; 100(10):2201-7. PubMed ID: 15139065
[TBL] [Abstract][Full Text] [Related]
40. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer.
Tomás JF; Pérez-Carrión R; Escudero A; López-Lorenzo JL; López-Pascual J; Fernández-Rañada JM
Bone Marrow Transplant; 1997 Feb; 19(4):331-6. PubMed ID: 9051242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
